Daunorubicin Production Cost Reports

The report provides a detailed analysis essential for establishing a daunorubicin production plant. It encompasses all critical aspects necessary for daunorubicin production, including the cost of daunorubicin production, daunorubicin plant cost, daunorubicin production costs, and the overall daunorubicin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a daunorubicin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Daunorubicin is a chemotherapy medicine that is mainly used in the treatment of certain types of cancer. It is widely utilised in the management of certain types of blood cancers, especially acute leukaemia. It is primarily prescribed for the treatment of acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). It works by slowing or stopping the growth of cancer cells by interfering with their DNA, which prevents them from multiplying. It finds its main application in combination chemotherapy regimens, where it is given along with other anticancer drugs to improve treatment outcomes. It is administered through intravenous injection under medical supervision in hospitals and specialised treatment centres. Additionally, it is also used in clinical research and oncology programs to develop and refine treatment protocols for hematologic cancers.

The market for daunorubicin is primarily driven by its application as an anticancer agent in the treatment of high-risk blood-related cancers, which supports its demand in oncology and cancer care. Its application as a chemotherapy drug for the treatment of acute leukaemia and AIDS-related Kaposi sarcoma significantly fuels its demand in the medical and pharmaceutical industries. Its application as a drug in combination with other anticancer medicines as part of standard chemotherapy regimens further promotes its demand in the medical and healthcare sectors. Its application in the research and biotechnology industries to explore its potential with additional chemotherapy agents to manage advanced leukaemias also drives its market growth. Moreover, advancements in pharmaceutical production technologies, secure supply chains, cold storage handling, and efficient distribution networks significantly impact industrial daunorubicin procurement. Factors such as the cost and availability of main raw materials, strict regulatory requirements, and compliance with quality and safety standards also influence its global procurement practices.

Raw Material for Daunorubicin Production

According to the daunorubicin production plant project report, the major raw materials for daunorubicin production include Streptomyces peucetius.

Production Process of Daunorubicin

The extensive daunorubicin production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of daunorubicin begins with the cultivation of the microorganism Streptomyces peucetius under controlled fermentation conditions to allow it to naturally produce the antibiotic in the broth. After sufficient growth and production, the fermentation mixture is filtered to remove the microbial cells, and the active compound is extracted from the broth using suitable organic solvents. Then, the crude extract is purified through a series of separation steps, such as solvent partitioning and chromatographic techniques, to remove impurities and closely related compounds. Finally, the purified product is crystallised and dried to obtain daunorubicin as the desired product.

Daunorubicin is an anthracycline antibiotic that is widely used as a chemotherapeutic agent. It appears as an orange-red to red crystalline powder with a needle-like crystal structure. The molecular formula of the compound is C₂₇H₂₉NO₁₀, and its molar mass is 527.52 g/mol. Its density is approximately 1.554 g/cm³, and it is soluble in water as well as in DMSO. The compound has a boiling point of approximately 770 degrees Celsius at 760 mmHg and a flash point of around 419.5 degrees Celsius. The compound decomposes at its melting point, which is in the range of 188-190 degrees Celsius. The compound is a confirmed carcinogen and mutagen, and it is acutely toxic if ingested or administered improperly. It is recommended to handle this substance with appropriate protective equipment in a well-ventilated area and store it under inert gas conditions. Extended exposure to daunorubicin may cause serious health complications, most notably dose-dependent cardiotoxicity, bone marrow suppression, and tissue necrosis if extravasation occurs at the injection site.